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Abstract
Background: Knowledge of the genotype of melanoma is important to guide patient management. Identification
of mutations in BRAF and c-KIT lead directly to targeted treatment, but it is also helpful to know if there are driver
oncogene mutations in NRAS, GNAQ or GNA11 as these patients may benefit from alternative strategies such as
immunotherapy.
Methods: While polymerase chain reaction (PCR) methods are often used to detect BRAF mutations, next generation
sequencing (NGS) is able to determine all of the necessary information on several genes at once, with potential
advantages in turnaround time. We describe here an Ampliseq hotspot panel for melanoma for use with the
IonTorrent Personal Genome Machine (PGM) which covers the mutations currently of most clinical interest.
Results: We have validated this in 151 cases of skin and uveal melanoma from our files, and correlated the data with
PCR based assessment of BRAF status. There was excellent agreement, with few discrepancies, though NGS does have
greater coverage and picks up some mutations that would be missed by PCR. However, these are often rare and of
unknown significance for treatment.
Conclusions: PCR methods are rapid, less time-consuming and less expensive than NGS, and could be used as triage
for patients requiring more extensive diagnostic workup. The NGS panel described here is suitable for clinical use with
formalin-fixed paraffin-embedded (FFPE) samples.
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Background
Driver genetic abnormalities within growth pathways can
be identified in most tumour types and define response to
targeted anti-cancer drugs. In melanoma, validated drug
targets with companion diagnostic utility now include
BRAF and c-KIT, as these are driver oncogenes in which
activating mutations occur (Fig. 1) and can be targeted by
tyrosine kinase inhibitors (TKIs). Demonstration of other
mutations in other driver oncogenes, particularly NRAS,
GNAQ and GNA11, can be useful in determining treat-
ment strategy, such as an early decision to use immuno-
therapy with CTLA4 or PDL1 inhibitors. The number of
drugs and the complexity of their associated companion
diagnostic pathways is increasing rapidly. Additional infor-
mation from gene and protein expression can also assist
comprehensive analysis of melanoma biology [1, 2].
Pathology laboratories need to provide a rapid, reliable
and comprehensive diagnostic molecular pathology ser-
vice to oncologists [3]. This is challenging, particularly
when diagnostics budgets are under pressure. However,
advances in the automation of DNA and RNA retrieval
from FFPE samples, as well as improvements in immu-
nohistochemistry mean that tumours can be charac-
terised rapidly for mutational status [4].
There are a large number of commercial methods
based on polymerase chain reaction (PCR) available for
BRAF determination in melanoma. Those most commonly
used include cobas® (Roche Diagnostics, Burgess Hill, UK)
and Therascreen® (Qiagen, Manchester, UK). Many labora-
tories still use older sequencing technologies including
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Sanger and Pyrosequencing, and the use of NGS methods
is becoming more common. Different methods tolerate dif-
ferent degrees of DNA quality, require different levels of
operator skill, and need different levels of expertise for
their interpretation [5]. Despite this, comparative studies
are relatively uncommon. A recent study compared Sanger
sequencing with cobas® for BRAF V600E mutation [6]. The
detection rate did not differ significantly, but six cases were
missed by cobas which does not cover all of the mutations
potentially present. Conversely, while cobas PCR produced
results in every case tested, Sanger sequencing failed in ten
cases [6]. Sanger sequencing usually has lower sensitivity
than targeted PCR, but the assays also have different re-
quirements for input DNA. Sensitivity is not the only issue:
the amount of input DNA required varies between tech-
nologies and can have a major effect on the feasibility of
testing small samples. The BRAF cobas test requires 125
ng input DNA, while the Sanger sequencing method used
in the study cited above [6] needed just 50 ng DNA [7].
TaqMan castPCR technology (ThermoFisher, Paisley, UK)
has been shown comparable to pyrosequencing [8], and re-
quires 50 ng of DNA per reaction in 96 well plates (200 ng
in total), but only 100 ng DNA per 48 wells in Taqman
array format [9], while Therascreen requires 80 ng DNA
per reaction (320 ng in total) [10]. The simplicity of the
PCR method chosen is also important to busy routine
pathology laboratories, where the availability of expert staff
is a major factor [5].
We recently participated in the validation of a 22 gene
Ampliseq panel for lung and colorectal cancer on the
IonTorrent Personal Genome Machine (PGM) (Thermo-
Fisher) [11], and have now designed a melanoma panel
covering all actionable melanoma mutations, though it
would also be feasible to use validated comprehensive
gene panel if this is preferred. Despite recent improve-
ments, NGS is challenging to use in a routine molecular
pathology environment and many laboratories still prefer
a PCR solution. Taqman Array™ technology (Thermo-
Fisher) can be used with castPCR mutation detection as-
says to provide an alternative and less expensive panel
testing facility to NGS methods [9]. Our current panel
incorporates KRAS, NRAS, EGFR, and BRAF for com-
bined screening of common mutations in colorectal cancer,
lung cancer and melanoma, known as the REB array [9].
While multiple gene PCR is helpful, there is also a
need for validated NGS solutions suitable for clinical use
to assist the molecular characterisation of melanoma,
particularly when these do not identify driver mutations.
We therefore compared our Ampliseq panel for use on
the IonTorrent PGM NGS platform with routine PCR
methods and the recently validated REB array.
Methods
The study was designed as a direct comparison between
multi-gene PCR (TaqMan™ array) and (IonTorrent) NGS
based against routine Therascreen® or cobas® testing for
BRAF alone.
Study population
A total of 151 samples were sourced from 2014 and
2015 from 132 melanoma patients attending University
Hospital Coventry and Warwickshire (UHCW) for diagno-
sis and treatment, including 18 uveal melanomas blocks
obtained from the Institute of Ophthalmology London for
comparison. All advanced melanomas are routinely tested
for BRAF, either in house, or at a referral centre using
Therascreen® (Qiagen, Manchester UK) or cobas® (Roche
Diagnostics, Burgess Hill, UK). Clinical data supplied with
Fig. 1 Growth pathway in melanoma, showing the genes included in the IonTorrent panel which can be targeted by tyrosine kinase inhibitors
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the specimens were collected from the Pathology Labora-
tory Information Management System (ULTRA, Cirdan,
Lisburn, Northern Ireland, UK). To ensure that all melan-
oma types can be handled, we have included 2 mucosal
and 4 acral lentiginous melanomas, as well as 18 uveal
melanomas.
DNA extraction
Areas of high cellularity melanoma (>50% neoplastic cells)
were marked on a slide by a histopathologist. These were
matched with the corresponding block. Samples from the
areas marked were then punched out using a 1 mm diam-
eter skin punch with plunger (Integra Miltex, Plainsboro,
NJ, USA). DNA extraction was performed using the Pro-
mega Maxwell™ instrument, according to the manufac-
turer’s instructions. DNA content and quality was checked
by Qubit 2.0 fluorimeter (ThermoFisher) according to the
manufacturer’s instructions using their HS dsDNA kit
before mutation detection. We used a volume of 1 μl
(less than 50 ng DNA) to conserve as much of the sample
as possible, and worked with a range of concentrations,
depending on the extraction concentration achieved.
REB Taqman array
CastPCR™ provides a platform for sensitive mutation de-
tection and in combination with TaqMan Array provides
a robust solution with minimal pipetting steps. Extracted
DNA (100 ng) is diluted with Taq polymerase and added
to a port of a manufactured microfluidic array [9]. TaqMan
arrays can be run on AB7900HT, ViiA7 and Quantstudio
PCR machines (ThermoFisher), although for this study, we
used the ViiA7 instrument. The REB array method re-
quires little operator time or experience: it covers all BRAF
mutations of relevance and >95% of reported NRAS
mutations.
IonTorrent NGS
The panel design was based on the Catalogue of Somatic
Mutations in Cancer (COSMIC) database and literature
searches, and included seven genes important in melanoma
tumorigenesis (Fig. 2, Table 1 and Additional file 1: Table
S1). A total 95 hotspot mutations in these genes were sub-
mitted to the Ampliseq designer tool (https://ampliseq.-
com/browse.action. The resultant primer pool
consisted of 21 primer pairs with 98% of predicted
coverage of the target region (hotspots COSM1139 and
COSM1142 were not included in the final design). The
final target region was 2.47kb with the amplicon range
125-175 bp in length. The codons listed for each gene
included in the Ampliseq panel are shown in Table 1.
Sequencing was performed as previously described [11],
with the following changes to accommodate IonChef load-
ing of the IonTorrent 314 chips. 10 ng of gDNA from
each of the samples chosen for NGS analysis was com-
bined with the Ampliseq™ reagents and primer pool for
the melanoma gene panel and amplified initially for 23 cy-
cles, which was later optimised to 28 cycles. After ini-
tial amplification, the amplified products were partially
digested before IonExpress Adapters and Barcode se-
quences were ligated to the library fragments. Following
barcoding the libraries were cleaned up using a magnetic
bead method (IonTorrent, ThermoFisher) and then quan-
tified by the Ampliseq Q-PCR method (ThermoFisher).
Once the libraries were successfully quantified they were
combined and diluted to 50 pM. For IonTorrent 314
chips, 7 libraries on average were combined per chip.
These library pools were then loaded into the IonChef
Fig. 2 Diagram showing the codons for each gene within the Ion Torrent melanoma panel: the majority of mutations tested were within BRAF,
NRAS and c-KIT
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instrument for further library preparation and chip load-
ing. The loaded 314 chips were then run on the IonTor-
rent PGM instrument according to manufacturer’s
instructions. The Variant Caller plugin (included in the
provided Ion Torrent Suite software version 4.2) was used
to analyse the aligned sequence data for the identification
of hotspot mutations and novel variants. The variant caller
files were subjected for further analysis with the Ion Re-
porter online tool. Coverage was regarded as acceptable if
mean was at least 300×, and the Variant caller default set-
ting interrogating somatic variants with high stringency
was used for hotspot calling, to exclude those < 2% allele
frequency. Only known mutations with COSMIC refer-
ences were included. For the purposes of this analysis,
SNPs and variants of unknown significance were ignored.
Data and economic analysis
A sample size of 150 biopsies is expected to be sufficient
to meet the need for comparison of the two methods,
based on an expected Kappa of 0.9, with a 2-tailed Null
value of 0.6 and 80% power. Data from both PCR (all
methods) and NGS were compared using kappa statistics,
and discrepant results tested independently by another la-
boratory. Costing data were obtained from timesheets and
invoice information held within the pathology laboratory
for use with the CMD Impact tool available on-line
from the Royal College of Pathologists (www.rcpath.org/
cmd-impact.html).
Ethics
The development of service improvements does not re-
quire specific research ethics committee approval as stated
in the EU Clinical Trials Directive (2001/20/EC). However,
in this instance, we obtained most samples from the Ar-
den Tissue Bank, (ATB15-001) which has NRES ethics ap-
proval (12/SC/0526) to conduct studies on anonymised
samples that are not required for diagnosis. In practice,
written consent for use of tissue was obtained from all pa-
tients as part of the surgical consent process.
Results
A total of 151 blocks from 148 resections were submitted
for NGS testing, representing 132 patients with repeat
samples available from metastases and primary tumours
in 11 patients. There were 76 males and 37 females with
cutaneous melanoma. The average age of the patients was
66 years (range 22 - 95 years, median 70 years). Duplicate
blocks were tested from the same sample for three sam-
ples repeated as controls, producing the same results in
each case.
Patients
A total of 105 patients had cutaneous melanoma (includ-
ing 4 acral lentiginous melanoma and 2 malignant blue
naevus), 2 had mucosal melanoma, 19 uveal melanomas
(18 primary, 1 metastatic), and 6 unknown primary site.
Mutations
The mutations identified in each group are summarized
in Table 2. Driver mutations were identified in 70% of
the patients studied, and in 74% of the cutaneous mela-
nomas (all types). BRAF was the commonest mutation
found, present in 44 of the 105 cutaneous patients
(42%). NRAS was present in 28 of the 105 cutaneous
melanomas (27%), and small numbers of KIT and MEK1
mutations were identified in cutaneous melanomas (3 and
4 cases respectively). Both mucosal melanomas tested
were wild-type, but 4 of the 6 melanomas of unknown pri-
mary origin had mutations, including one GNAQ muta-
tion suggesting that this might have been of uveal origin.
Mutations were found in 10 of the 19 uveal melanomas,
with equal numbers of GNA11 and GNAQ mutations,
but there were also two NRAS mutations.
BRAF correlation
No molecular pathology was done routinely by the path-
ologist in 33 cases, mainly due to the presence of inter-
current disease, and the 19 historical uveal melanoma
cases. In the remaining 80 cases, molecular investigation
for BRAF mutations was done by cobas PCR. For BRAF,
Table 1 Summary of custom Ampliseq gene panel for melanoma, including common driver mutations in BRAF, KRAS, NRAS, MEK,
GNAQ, and GNA11
Gene Reference Codons included Number of Mutations
BRAF NM_004333.4 466, 469, 583, 584, 586, 592, 594, 595, 597, 600, 601, 605, 614, 618 29
GNAQ NM_002072.3 209, 359 6
GNA11 NM_002067.2 183, 209, 223 3
NRAS NM_002524.4 12, 13, 18, 50, 59, 61, 68 7
c-KIT NM_000222.2 553, 557, 559, 560, 566, 569, 576, 642, 655, 816, 820, 822, 823, 829, 853 18
KRAS NM_033360 12, 61 5
MEK1/MAP2K1 NM_002755.2 111, 124, 203, 264 5
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patient-based correlation with cobas detection in 80/132
cases was 92.5%, with six discrepancies, as shown in
Table 3. For the 33 cases without cobas, the REB array
was run with residual DNA from the NGS sample. The
assay failed in 2 cases, but resulted in a further 15 cases
with complete correlation BRAF mutation between
PCR and NGS, including 2 cases with V600K mutations:
the remainder were confirmed as wild-type (100%
correlation).
Other mutations
NRAS is present on the REB array (though not on
cobas) and was completely concordant in 5 samples
found to have the Q61R mutation founds by NGS. Three
KIT mutations were identified (Table 2), and correlated
with known KIT mutations by pyrosequencing performed
at University Hospital Birmingham in 2 cases, which was
from a skin primary and melanoma from an unknown pri-
mary site. MEK mutation was seen in 1 case, which was
under treatment with a BRAF inhibitor (vemurafenib),
and a KIT mutation was identified in another case on
treatment (Table 3).
The costs of NGS are compared with the PCR Taqman
Array previously published in Table 4, showing that PCR
is less expensive at £135 per case than NGS at £257 per
case. There are differences in the cost of reagents, but
the major difference in costs is due to the staff costs for
NGS (£ per case) in comparison with PCR (£ per case).
Discussion
Our results validate the use of a custom design targeted
Ampliseq panel for melanoma mutation detection. Our
panel includes the genes commonly mutated in ocular
(uveal) and mucosal melanoma as well as the more com-
mon cutaneous tumours. The panel described here has
been used in one patient with metastatic melanoma who
had a history of both skin and uveal primary lesions.
The clinical question being which one had given rise to
his metastatic disease. The sample contained a GNA11
mutation, indicative of metastasis from the uveal tumour.
We provide further evidence for the utility of the REB
array in melanoma, and this could be used to triage sam-
ples for the more expensive NGS method, which has a
longer turnaround time (90 min compared with 2 days,
from DNA to result). However, it should be noted that
rapid turnaround is of limited clinical relevance to mel-
anoma patients, unless they present with widespread
metastases.
The ability of NGS to look for MEK mutations associ-
ated with resistance to vemurafenib may be helpful in
guiding patient treatment, and there is a case to be made
for re-testing of samples taken on progression. In this
series, only two patients had documented resistance, one
of whom developed a MEK mutation, while the other had
a KIT mutation, both of which are potentially treatable.
Ampliseq™ provides targeted NGS for hotspots. The
NRAS and BRAF primers used have been previously
Table 2 Summary of mutations identified by melanoma type
Melanoma Type BRAF NRAS KRAS KIT MEK GNA11 GNAQ WT Total
Cutaneous SSM 15 11 0 1 1 0 0 6 34
Cutaneous Nodular 15 11 0 0 1 0 0 11 38
Cutaneous NOS 12 3 0 1 1 0 0 5 22
LMM 1 2 0 0 0 0 0 2 5
Acral Lentiginous 0 1 0 0 1 0 0 2 4
Malignant blue naevus 1 0 0 0 0 0 0 1 2
Mucosal 0 0 0 0 0 0 0 2 2
Unknown Primary 0 3 0 1 0 0 1 1 6
Uveal 0 2 0 0 0 4 4 9 19
Total 44 33 0 3 4 4 5 39 132
Table 3 Discrepancies between cobas PCR for BRAF and NGS. As cobas does not distinguish mutations at BRAF codon 600, these
are designated V600X in the table, WT is wild-type
Case (Sample) cobas NGS Comment True discrepancy
30 WT BRAF Mutation not present on cobas Yes
33 WT BRAF Mutation not present on cobas Yes
35 WT BRAF Mutation not present on cobas Yes
48 V600X MEK1 Resistance gene due to vemurafenib treatment No
85 V600X NRAS Resistance gene due to vemurafenib treatment No
100 V600X KIT Resistance gene due to vemurafenib treatment No
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validated with the 22 gene Onconetwork IonTorrent
PGM panel which includes both [11]. For known muta-
tions, results from variant caller can be obtained directly
or uploaded to IonReporter for more detailed analysis.
We chose the former approach, due to security of data
concerns which prevent us from routinely uploading
data to IonReporter over non-hospital systems. However,
the default IonTorrent analysis settings worked well in
this study and variant caller does provide COSMIC ref-
erences for known variants, allowing rapid checking of
mutations for individual samples.
Comparison of different methods is important, but can
be complicated. Each method designed to identify ac-
tionable mutations or hotspots, rather than to sequence
entire genes, has slightly differing coverage, and differing
sensitivity for each mutation included. Discrepancies be-
tween methods are therefore inevitable and expected. In-
vestigation usually reveals that such discrepancies often
involve rare variants or variants of unknown significance.
We have identified a number of comparative studies in
the literature, but perhaps less than one might expect
given the number of methods commercially available,
let alone those used as in-house laboratory-developed
(‘homebrew’) tests. The majority of these compare in-
house tests with Sanger sequencing and commercially
available PCR assays, with some variation in sensitivity,
but few discrepancies overall [4, 6, 12–16]. There are
the expected issues with coverage: for instance, some
PCR methods do not detect the relatively common
V600K mutation [16]. If there is a clinical need to iden-
tify other mutations than those tested, the use of cas-
cade testing with other methods should be considered.
We now use the REB array [9] as a triage for NGS:
those patients who show a BRAF or NRAS mutation
can be excluded from further testing, while those in
whom it is clinically relevant to identify other driver
mutations (e.g. c-KIT) can be pursued further.
The costs of the two methods differ substantially
(Table 4). As expected, the REB array proved much less
expensive than NGS, but also has less coverage. In real-
ity, the REB array can be used to exclude tumours with
common BRAF or NRAS mutations from further testing,
allowing resources to be concentrated on sequencing
cases where the driver mutation is not known, and know-
ledge of the KIT status of the tumour may be helpful. This
is not a large panel, and we rarely require NGS on more
than 8 patients at a time, and we therefore selected the
314 chip as optimal. The number of cases could be scaled
up for the 316 and 318 chips, but this is unlikely to alter
the cost per patient. The degree of automation now avail-
able using the IonChef™ for chip loading releases operator
time, but library preparation is not yet automated and
NGS does need considerable molecular pathology expert-
ise. This is the major source of the increased cost of NGS
in comparison with PCR methods, and should decline as
automation is introduced.
Conclusion
The methods compared here all have the ability to find
mutations within melanoma, particularly those in BRAF.
We have found it helpful to know of NRAS mutations to
manage resources, and increasingly to direct patients to-
wards immunotherapy at an earlier stage of their manage-
ment. Those without an identified driver mutation may
well benefit from the NGS approach used here, or a more
comprehensive panel, depending upon workflow within
the laboratory.
Additional file
Additional file 1: Table S1. Complete mutation hotspot list included in
Custom Ampliseq gene panel for melanoma, including common driver
mutations in BRAF, NRAS, KRAS, MEK, GNAQ, and GNA11. (DOCX 125 kb)
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method for our laboratory. The major differences are due to the
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Cost of consumables per test 40 134
External quality assurance 6 5
Equipment rental and maintenance 35 45
Staff costs 54 73
Total per sample 135 257
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